Exclusive: Clearmind And SciSparc To Conduct Study Evaluating Psychedelics And CannAmide Based Drug For Treatment Of Obesity And Metabolic Syndrome
Portfolio Pulse from Vuk Zdinjak
Clearmind Medicine and SciSparc have entered into a research agreement with the Hebrew University of Jerusalem to evaluate their combination treatment for obesity and metabolic syndrome. The study will be led by Professor Joseph Tam and will assess the effects of Clearmind's MEAI and SciSparc's PEA on food intake, metabolic and activity profiles.
June 16, 2023 | 12:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Clearmind Medicine partners with SciSparc and Hebrew University of Jerusalem to evaluate their combination treatment for obesity and metabolic syndrome.
The partnership with SciSparc and Hebrew University of Jerusalem to evaluate the combination treatment for obesity and metabolic syndrome could potentially lead to positive results and increased interest in Clearmind's MEAI compound. This may have a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
SciSparc collaborates with Clearmind Medicine and Hebrew University of Jerusalem to evaluate their combination treatment for obesity and metabolic syndrome.
The collaboration with Clearmind Medicine and Hebrew University of Jerusalem to evaluate the combination treatment for obesity and metabolic syndrome could potentially lead to positive results and increased interest in SciSparc's PEA compound. This may have a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50